ID: h-cf07e38ecd
Hypothesis
Synergistic reduction of amyloid-tau interaction through secondary effects
Cancer/cystatin-C-mediated amyloid reduction decreases amyloid-nucleated tau pathology through reduced BACE1 activity and GSK3β activation.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 7 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Cancer/cystatin-C-mediated amyloid reduction decreases amyloid-nucleated tau pathology through reduced BACE1 activity and GSK3β activation. This hypothesis is almost certainly true but uninformative—it re-explains known downstream biology rather than identifying a novel mechanism. Should be demoted from 'mechanism' to 'expected downstream consequence of amyloid lowering.'
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["APP Substrate<br/>Amyloid Precursor Protein"]
B["BACE1 Cleavage<br/>beta-Secretase Activity"]
C["Amyloid-beta Oligomers<br/>Neurotoxic Aggregates"]
D["GSK3beta Activation<br/>Kinase Dysregulation"]
E["Tau Hyperphosphorylation<br/>AT180 and PHF-1 Epitopes"]
F["Neurofibrillary Tangles<br/>Tau Aggregation Pathology"]
G["BACE1 Inhibition or<br/>Amyloid Lowering Strategy"]
H["GSK3beta Suppression<br/>Indirect via Reduced Abeta"]
I["Tau Pathology Reduction<br/>Secondary Therapeutic Effect"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"inhibits"| B
G --> H
H -.->|"reduces"| D
H --> I
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784
style I fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix7 supports2 contradicts
Supports
Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged β-amyloid nanoscavenger for Alzheimer's disease therapy.
Supports
Combination strategy employing BACE1 inhibitor and memantine to boost cognitive benefits in Alzheimer's disease therapy.
Supports
From BACE1 inhibitor to multifunctionality of tryptoline and tryptamine triazole derivatives for Alzheimer's disease.
Supports
Concurrent Treatment with Taxifolin and Cilostazol on the Lowering of β-Amyloid Accumulation and Neurotoxicity via the Suppression of P-JAK2/P-STAT3/NF-κB/BACE1 Signaling Pathways.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — BACE1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for BACE1/GSK3β from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for BACE1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.3%
Volatility
Low
0.0112
Events (7d)
2
Price History
▼0.3%💾 Resource Usage
LLM Tokens
11,154
$0.0335
Total Cost
$0.0335
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF early-stage Alzheimer's disease patients receive amyloid-lowering therapy (BACE1 inhibitor or anti-amyloid antibody) achieving >60% reduction in brain amyloid PET signal for 18 months THEN CSF p-ta | CSF p-tau181 will be 25-40% lower in the amyloid-reduction group vs. placebo, with GSK3β activity (assessed via p-GSK3β S9/total GSK3β ratio in PBMCs) declining | — no observation — | pending | 0.65 |
| IF iPSC-derived cortical neurons from early-onset familial AD patients (PSEN1/APP mutations) are treated with selective BACE1 inhibitor (reducing BACE1 activity ≥85%) for 14 days THEN phosphorylated t | p-tau396 reduced 35-50%; total tau reduced 15-25%; synaptic density increased 20-40%; p-GSK3β S9 increased 40-70%; amyloid β40/42 secretion reduced ≥70%. | — no observation — | pending | 0.58 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF early-stage Alzheimer's disease patients receive amyloid-lowering therapy (BACE1 inhibitor or anti-amyloid antibody) achieving >60% reduction in brain amyloid PET signal for 18 months THEN CSF p-tau181 concentrations will decrease by ≥25% compared to placebo-treated controls, with greater reducti
Predicted outcome: CSF p-tau181 will be 25-40% lower in the amyloid-reduction group vs. placebo, with GSK3β activity (assessed via p-GSK3β S9/total GSK3β ratio in PBMCs)
Falsification: CSF p-tau181 remains unchanged or increases by >10% despite verified amyloid reduction, or GSK3β activity does not correlate with amyloid burden changes; this would indicate tau pathology proceeds ind
pendingconf 58%
IF iPSC-derived cortical neurons from early-onset familial AD patients (PSEN1/APP mutations) are treated with selective BACE1 inhibitor (reducing BACE1 activity ≥85%) for 14 days THEN phosphorylated tau at S396 (p-tau396) will decrease by ≥35% and synaptic markers (synapsin-1, PSD95) will increase b
Predicted outcome: p-tau396 reduced 35-50%; total tau reduced 15-25%; synaptic density increased 20-40%; p-GSK3β S9 increased 40-70%; amyloid β40/42 secretion reduced ≥7
Falsification: p-tau396 shows <15% reduction or increases despite verified BACE1 inhibition (>85% enzymatic activity reduction), indicating tau pathology can propagate independently of amyloid-driven BACE1 activity;
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.